These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9438509)

  • 1. Dynamic contrast-enhanced magnetic resonance imaging in a model of splenic metastasis.
    Runge VM; Williams NM
    Invest Radiol; 1998 Jan; 33(1):45-50. PubMed ID: 9438509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal metastasis. Detection and characterization on enhanced magnetic resonance imaging using an animal model.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1997 Apr; 32(4):212-7. PubMed ID: 9101356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast-enhanced magnetic resonance imaging in a spinal epidural tumor model.
    Runge VM; Lee C; Iten AL; Williams NM
    Invest Radiol; 1997 Oct; 32(10):589-95. PubMed ID: 9342117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detectability of small liver metastases with gadolinium BOPTA.
    Runge VM; Lee C; Williams NM
    Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Dec; 31(12):781-8. PubMed ID: 8970881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging of experimental pyelonephritis in rabbits.
    Runge VM; Timoney JF; Williams NM
    Invest Radiol; 1997 Nov; 32(11):696-704. PubMed ID: 9387058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early dynamic magnetic resonance imaging of liver metastases with 0.3 and 0.6 mmol/kg gadoteridol injection.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Aug; 31(8):472-8. PubMed ID: 8854193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of standard and high-dose contrast-enhanced breath-hold liver magnetic resonance for visualization of metastatic disease in an animal model.
    Runge VM
    Invest Radiol; 1998 May; 33(5):263-7. PubMed ID: 9609484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging in a spinal abscess model. Preliminary report.
    Runge VM; Williams NM; Lee C; Timoney JF
    Invest Radiol; 1998 Apr; 33(4):246-55. PubMed ID: 9556750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of gadolinium Cy2DOTA, a new hepatobiliary agent, and gadolinium HP-DO3A, an extracellular agent, in healthy liver and metastatic disease.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1995 Feb; 30(2):123-30. PubMed ID: 7782188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging of an experimental model of intracranial metastatic disease. A study of lesion detectability.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1994 Dec; 29(12):1050-6. PubMed ID: 7721546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose applications of gadolinium chelates in magnetic resonance imaging.
    Runge VM; Kirsch JE; Thomas GS
    Magn Reson Med; 1991 Dec; 22(2):358-63. PubMed ID: 1812371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings.
    Grazioli L; Morana G; Caudana R; Benetti A; Portolani N; Talamini G; Colombari R; Pirovano G; Kirchin MA; Spinazzi A
    Invest Radiol; 2000 Jan; 35(1):25-34. PubMed ID: 10639033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic gadolinium-enhanced MR imaging of the spleen: normal enhancement patterns and evaluation of splenic lesions.
    Mirowitz SA; Brown JJ; Lee JK; Heiken JP
    Radiology; 1991 Jun; 179(3):681-6. PubMed ID: 2027974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging of osteoid osteoma with dynamic gadolinium-enhanced MR imaging.
    Liu PT; Chivers FS; Roberts CC; Schultz CJ; Beauchamp CP
    Radiology; 2003 Jun; 227(3):691-700. PubMed ID: 12773675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal liver lesions: SPIO-, gadolinium-, and ferucarbotran-enhanced dynamic T1-weighted and delayed T2-weighted MR imaging in rabbits.
    Schnorr J; Wagner S; Abramjuk C; Drees R; Schink T; Schellenberger EA; Pilgrimm H; Hamm B; Taupitz M
    Radiology; 2006 Jul; 240(1):90-100. PubMed ID: 16684917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of cerebral perfusion by first-pass, dynamic, contrast-enhanced, steady-state free-precession MR imaging: an animal study.
    Runge VM; Kirsch JE; Wells JW; Woolfolk CE
    AJR Am J Roentgenol; 1993 Mar; 160(3):593-600. PubMed ID: 8430562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic contrast-enhanced magnetic resonance imaging evaluation of VX2 carcinoma in a rabbit model: comparison of 1.0-M gadobutrol and 0.5-M gadopentetate dimeglumine.
    Chang JM; Moon WK; Cha JH; Jung EJ; Cho N; Kim SJ
    Invest Radiol; 2010 Oct; 45(10):655-61. PubMed ID: 20808238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
    Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB
    Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.